Janney Montgomery Scott Begins Coverage on PLx Pharma (PLXP)

Janney Montgomery Scott initiated coverage on shares of PLx Pharma (NASDAQ:PLXP) in a research report released on Friday morning, Briefing.com Automated Import reports. The firm issued a buy rating on the biotechnology company’s stock.

PLXP has been the topic of several other research reports. Zacks Investment Research lowered shares of PLx Pharma from a hold rating to a sell rating in a research note on Wednesday, January 9th. ValuEngine raised shares of PLx Pharma from a sell rating to a hold rating in a research note on Wednesday, January 2nd. Raymond James lowered shares of PLx Pharma from an outperform rating to a market perform rating in a research note on Monday, January 14th. Finally, JMP Securities started coverage on shares of PLx Pharma in a research note on Thursday, March 14th. They issued an outperform rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $4.75.

PLXP opened at $5.40 on Friday. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $47.25 million, a price-to-earnings ratio of -4.00 and a beta of 5.33. PLx Pharma has a 1-year low of $1.00 and a 1-year high of $6.44.

PLx Pharma (NASDAQ:PLXP) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. The firm had revenue of $0.29 million during the quarter. PLx Pharma had a net margin of 1.09% and a negative return on equity of 186.01%. As a group, equities research analysts forecast that PLx Pharma will post -1.15 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc boosted its stake in shares of PLx Pharma by 98.0% in the 3rd quarter. Vanguard Group Inc now owns 163,431 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 80,910 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of PLx Pharma by 98.0% in the 3rd quarter. Vanguard Group Inc. now owns 163,431 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 80,910 shares during the last quarter. Finally, Park West Asset Management LLC boosted its stake in shares of PLx Pharma by 37.0% in the 4th quarter. Park West Asset Management LLC now owns 1,473,218 shares of the biotechnology company’s stock valued at $2,254,000 after purchasing an additional 397,495 shares during the last quarter. 24.24% of the stock is currently owned by institutional investors.

About PLx Pharma

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Recommended Story: Do stock splits help investors?

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.